Framingham, Massachusetts — October 10, 2025 — Leads & Copy — Xenetic Biosciences, Inc. (NASDAQ:XBIO) announced the pricing of its underwritten offering of 735,000 shares of common stock at $6.12 per share, projecting gross proceeds of approximately $4.5 million.
The biopharmaceutical company will offer all shares. It anticipates the closing of the offering around October 14, 2025, pending customary closing conditions. Canaccord Genuity is the sole bookrunner.
Xenetic plans to use the net proceeds for working capital and general corporate purposes. The offering is pursuant to a shelf registration statement on Form S-3, which the SEC declared effective on November 1, 2024.
The final prospectus supplement will be available on the SEC’s website. Copies can be obtained from Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, Suite 3000, Boston, Massachusetts 02109, or by telephone at (617) 371-3900, or by email at prospectus@cgf.com.
Jenene Thomas of JTC Team, LLC can be reached at (908) 824-0775 or xbio@jtcir.com.
Source: Xenetic Biosciences, Inc.
